Skip to main content

Table 3 Univariate and multivariate analysis for overall survival

From: Pre-treatment metastatic growth rate is associated with clinical outcome in patients with metastatic renal cell carcinoma treated with nivolumab

OS

Univariate analysis

Multivariate analysis

HR

95% CI

p-value

HR

95% CI

p-value

Age (above vs. below median)

2.04

0.663–6.261

0.21

   

sex (male vs. female)

0.71

0.19–2.61

0.61

   

IMDC (poor vs. fav/inter)

5.37

1.63–17.8

0.006

2.53

0.72–8.94

0.15

NLR (above vs. below median)

2.82

0.86–9.23

0.09

   

CRP (above vs. below median)

0.71

0.23–2.17

0.54

   

Line (3rd ≤ vs.2nd)

1.09

0.35–3.33

0.89

   

MGR (2.2 ≥ vs. 2.2 <)

6.99

1.84–26.6

0.004

5.27

1.25–22.4

0.02

Back to article page

BMC Urology

ISSN: 1471-2490

Contact us